503,079 Shares in Novo Nordisk A/S (NYSE:NVO) Acquired by OLD Mission Capital LLC

OLD Mission Capital LLC acquired a new position in Novo Nordisk A/S (NYSE:NVO - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 503,079 shares of the company's stock, valued at approximately $43,275,000. Novo Nordisk A/S accounts for about 0.7% of OLD Mission Capital LLC's portfolio, making the stock its 12th largest holding.

Several other hedge funds have also modified their holdings of NVO. Mosaic Financial Group LLC grew its stake in Novo Nordisk A/S by 180.7% in the 4th quarter. Mosaic Financial Group LLC now owns 4,856 shares of the company's stock valued at $418,000 after acquiring an additional 3,126 shares during the period. HighPoint Advisor Group LLC lifted its holdings in Novo Nordisk A/S by 4.5% during the fourth quarter. HighPoint Advisor Group LLC now owns 19,348 shares of the company's stock valued at $1,620,000 after purchasing an additional 841 shares in the last quarter. Meridian Investment Counsel Inc. grew its position in shares of Novo Nordisk A/S by 95.4% in the fourth quarter. Meridian Investment Counsel Inc. now owns 45,697 shares of the company's stock valued at $3,931,000 after purchasing an additional 22,314 shares during the period. Family Legacy Inc. increased its stake in shares of Novo Nordisk A/S by 5.0% during the fourth quarter. Family Legacy Inc. now owns 18,557 shares of the company's stock worth $1,589,000 after purchasing an additional 884 shares in the last quarter. Finally, Cannell & Spears LLC boosted its holdings in Novo Nordisk A/S by 636.3% in the 4th quarter. Cannell & Spears LLC now owns 36,677 shares of the company's stock worth $3,155,000 after buying an additional 31,696 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Novo Nordisk A/S Trading Up 0.2 %

NVO stock traded up $0.17 during trading on Wednesday, reaching $68.20. 7,301,268 shares of the stock were exchanged, compared to its average volume of 5,588,205. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $306.05 billion, a price-to-earnings ratio of 20.73, a P/E/G ratio of 0.90 and a beta of 0.42. The business has a 50 day moving average price of $81.89 and a 200-day moving average price of $97.68. Novo Nordisk A/S has a 1 year low of $66.58 and a 1 year high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S's dividend payout ratio (DPR) is presently 47.72%.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on NVO shares. BMO Capital Markets reduced their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating for the company in a report on Monday, December 23rd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Finally, UBS Group upgraded shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a report on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.